This compilation represents abstracts of presentations at the first meeting of the Initiative Group for the Central European Hepatologic Collaboration (CEHC, Warsaw, 19-21 November, 2015) on topics with special interest from four Central European countries and includes a summary of a boceprevir-based triple therapy cohort programme (from Hungary), current trends and challenges in liver diseases (from Poland), acute kidney injury in liver cirrhosis (from Slovakia) and treatment of hepatitis C in haemodialysed patients (from the Czech Republic). All these topics are or have been of high interest during the last several years, and many of them are still not completely resolved with the emergence and availability of the novel interferon-free therapies for hepatitis C and with other advances in the pathophysiology and treatment of liver diseases.

Department of Hepatogastroenterology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Infectious Diseases and Hepatology Medical University in Bialystok Bialystok Poland

HEGITO of Department Internal Medicine 2 Slovak Medical University BA F D Roosevelt University Hospital Banska Bystrica Slovakia

Somogy County Kaposi Mór Teaching Hospital Kaposvár Hungary

Zobrazit více v PubMed

Stępień M, Czarkowski MP. Hepatitis B in Poland in 2011. Przegl Epidemiol. 2013;67:239–245. PubMed

Rybacki M, Piekarska A, Wiszniewska M, et al. Hepatitis B and C infection: is it a problem in Polish healthcare workers? Int J Occup Med Environ Health. 2013;26:430–439. PubMed

World Health Organization. Global Status Report on Alcohol and Health. 2014. http://apps.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf?ua=1.

Janszky I, Vatten L, Romundstad L, et al. Metabolic syndrome in Poland – POND study. Ann Agric Environ Med. 2011;18:270–272. PubMed

Raszeja-Wyszomirska J, Kurzawski G, Lawniczak M, et al. Non-alcoholic liver disease and HFE mutation: a Polish study. World J Gastroenterol. 2010;16:2531–2536. PubMed PMC

Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176. PubMed

Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–1318. PubMed PMC

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417. PubMed

Wong F, Nadim MK, Kellum JA, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60:702–709. PubMed

Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48:2064–2077. PubMed

Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57:753–762. PubMed PMC

Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59:474–481. PubMed

Piano S, Rosi S, Maresio G, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59:482–489. PubMed

Cholongitas E, Calvaruso V, Senzolo M, et al. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol. 2009;24:1639–1647. PubMed

Altamirano J, Fagundes C, Dominguez M, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;10:65–71.e3. PubMed

Sperl J, Frankova S, Senkerikova R, et al. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. World J Gastroenterol. 2015;21:5496–5504. PubMed PMC

Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:549–557. PubMed PMC

Morales JM, Marcén R, Andres A, et al. Renal transplantation in patients with hepatitis C virus antibody. A long national experience. NDT Plus. 2010;3(Suppl 2):ii41–ii46. PubMed PMC

Goodkin DA, Bieber B, Gillespie B, et al. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38:405–412. PubMed

Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1 – patients with end-stage renal disease on hemodialysis or GFR > 30 ml/min. Liver Int. 2015 Nov 19; doi: 10.1111/liv.13025. [Epub ahead of print] PubMed DOI

Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal-disease: The Ruby-I Study. San Francisco: AASLD; 2015.

Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545. PubMed